Last reviewed · How we verify
Jintropin AQ
Jintropin AQ is a Small molecule drug developed by Changchun GeneScience Pharmaceutical Co., Ltd.. It is currently in Phase 2 development. Also known as: Somatropin injectable solution,rhGH injection.
Jintropin AQ is a pegylated Somatropin, a recombinant human growth hormone injection used to treat conditions such as Growth Hormone Deficiency, Prader-Willi Syndrome, and Dwarfism. It is a small molecule modality, classified as a recombinant human growth hormone injection.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Jintropin AQ |
|---|---|
| Also known as | Somatropin injectable solution,rhGH injection |
| Sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome (PHASE3)
- Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children (PHASE2)
- Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (PHASE3)
- Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jintropin AQ CI brief — competitive landscape report
- Jintropin AQ updates RSS · CI watch RSS
- Changchun GeneScience Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Jintropin AQ
What is Jintropin AQ?
Who makes Jintropin AQ?
Is Jintropin AQ also known as anything else?
What development phase is Jintropin AQ in?
Related
- Manufacturer: Changchun GeneScience Pharmaceutical Co., Ltd. — full pipeline
- Also known as: Somatropin injectable solution,rhGH injection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing